Document is current

Article History

Received: 12 January 2026

Accepted: 11 March 2026

First Online: 1 April 2026

Declarations

:

: The following authors declare no conflict of interest for this manuscript: ML, PB, BJ. AH is an Editorial Board member of Clinical Pharmacokinetics . AH was not involved in the selection of peer reviewers for the manuscript nor for any of the subsequent editorial decisions. NS provided consultation or attended advisory boards for Boehringer Ingelheim, Bristol-Myers Squibb, Ellipses Pharma, GlaxoSmithKline, Incyte; received research grants from Abbvie, Actuate Therapeutics, Amgen, Anaveon, Ascendis Pharma, AstraZeneca, Bayer, Blueprint Medicines, Boehringer Ingelheim, Bristol-Myers Squibb, CellCentric, Cogent Biosciences, Cresecendo Biologics, Deciphera, Exelixis, Genentech, GlaxoSmithKline, IDRx, Immunocore, Incyte, Janssen, Kling Biotherapeutics, Lixte, Merck, Merck Sharp & Dohme, Merus, Molecular Partners, Novartis, Pfizer, Revolution Medicin, Roche, Sanofi, Seattle Genetics, Taiho, Zentalis. All outside the submitted work, all payment to the Netherlands Cancer Institute. TS provided consultation or attended advisory boards for Ellipses Pharma. All outside the submitted work, all payment to the Netherlands Cancer Institute.

: There was no ethical approval required for this study.

: All data analysed in this study were obtained from MEDLINE database at

: Not applicable.

: Not applicable.

: Not applicable.

: Conceptualisation: ML, NS, AH; Literature search: ML Writing – Original Draft: ML; Writing – Review & Editing: ML, PB, BJ, TS, NS, AH; Supervision: NS, AH . The corresponding author attests that all listed authors meet authorship criteria and that no others meeting the criteria have been omitted. All contributors have approved the final manuscript and agree to its submission.